Search

Your search keyword '"Saus, Carlos"' showing total 26 results
Start Over Author "Saus, Carlos"
26 results on '"Saus, Carlos"'

1. Clinical and pathological features of Merkel cell carcinoma: A 4-year follow-up observational retrospective study in Spain

Author

Ríos-Martín, Juan José, Rodriguez-Salas, Nuria, Vázquez-Doval, Francisco Javier, Llombart, Beatriz, Rojas-Ferrer, Nohelia, González-Vela, M. Carmen, Zulueta, Teresa, Monteagudo, Carlos, Aneiros-Fernández, José, Beato, María José, Carrillo, Rosario, Silva-Carmona, Mary Yohana, Ayala, María, Gallego, Elena, Rodríguez-Peralto, José Luís, Fraga-Fernández, Javier, Fernández-Figueras, María Teresa, Barranco, Carlos, Córdoba, Alicia, Sanz-Zorrilla, Alicia, Ferrer, Berta, Fúnez, Rafael, Santonja, Carlos, Saus, Carlos, Idoate, Miguel Angel, Santos-Briz, Angel, Onrubia, José, Pinedo, Fernando, and de las Peñas, Ramón

Published
2022
Full Text
View/download PDF

3. SUPPLEMENTARY MATERIALS AND METHODS from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

Author

Alemany, Regina, primary, Moura, David S., primary, Redondo, Andres, primary, Martinez-Trufero, Javier, primary, Calabuig, Silvia, primary, Saus, Carlos, primary, Obrador-Hevia, Antonia, primary, Ramos, Rafael, primary, Villar, Victor H., primary, Valverde, Claudia, primary, Vaz, Maria Angeles, primary, Medina, Javier, primary, Felipe-Abrio, Irene, primary, Hindi, Nadia, primary, Taron, Miguel, primary, and Martin-Broto, Javier, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 2S - Lineweaver-Burk diagram for the substrate RH123 (A) and CFDA (B) in the absence (vehicle, DMSO) or presence of nilotinib (1-10 μM). from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

Author

Alemany, Regina, primary, Moura, David S., primary, Redondo, Andres, primary, Martinez-Trufero, Javier, primary, Calabuig, Silvia, primary, Saus, Carlos, primary, Obrador-Hevia, Antonia, primary, Ramos, Rafael, primary, Villar, Victor H., primary, Valverde, Claudia, primary, Vaz, Maria Angeles, primary, Medina, Javier, primary, Felipe-Abrio, Irene, primary, Hindi, Nadia, primary, Taron, Miguel, primary, and Martin-Broto, Javier, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 3S - Relative mRNA expression of ABCB1 (P-gp) and ABCC1 (MRP-1) in pre- and post-treatment formalin-fixed paraffin-embedded (FFPE) tumor samples. from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

Author

Alemany, Regina, primary, Moura, David S., primary, Redondo, Andres, primary, Martinez-Trufero, Javier, primary, Calabuig, Silvia, primary, Saus, Carlos, primary, Obrador-Hevia, Antonia, primary, Ramos, Rafael, primary, Villar, Victor H., primary, Valverde, Claudia, primary, Vaz, Maria Angeles, primary, Medina, Javier, primary, Felipe-Abrio, Irene, primary, Hindi, Nadia, primary, Taron, Miguel, primary, and Martin-Broto, Javier, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 1S - Real time cell growth monitorization of synovial sarcoma SW982 cells upon sequential treatment with nilotinib and doxorubicin. from Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

Author

Alemany, Regina, primary, Moura, David S., primary, Redondo, Andres, primary, Martinez-Trufero, Javier, primary, Calabuig, Silvia, primary, Saus, Carlos, primary, Obrador-Hevia, Antonia, primary, Ramos, Rafael, primary, Villar, Victor H., primary, Valverde, Claudia, primary, Vaz, Maria Angeles, primary, Medina, Javier, primary, Felipe-Abrio, Irene, primary, Hindi, Nadia, primary, Taron, Miguel, primary, and Martin-Broto, Javier, primary

Published
2023
Full Text
View/download PDF

17. Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma

Author

Alemany, Regina, primary, Moura, David S., additional, Redondo, Andres, additional, Martinez-Trufero, Javier, additional, Calabuig, Silvia, additional, Saus, Carlos, additional, Obrador-Hevia, Antonia, additional, Ramos, Rafael, additional, Villar, Victor H., additional, Valverde, Claudia, additional, Vaz, Maria Angeles, additional, Medina, Javier, additional, Felipe-Abrio, Irene, additional, Hindi, Nadia, additional, Taron, Miguel, additional, and Martin-Broto, Javier, additional

Published
2018
Full Text
View/download PDF

18. How should I treat a patient with an entrapped infected permanent pacemaker lead?

Author

Asmarats, Luis, primary, Maristany, Jaume, additional, Pons, Jaume, additional, Buendía, Siro, additional, Gómez-Jaume, Alfredo, additional, Saus, Carlos, additional, Macaya, Fernando, additional, Pascual, Marcos, additional, Bethencourt, Armando, additional, Van Malderen, Sophie, additional, Szili-Torok, Tamas, additional, Lever, Nigel, additional, and Webster, Mark, additional

Published
2014
Full Text
View/download PDF

19. Normalization of sphingomyelin levels by 2-hydroxyoleic acid induces autophagic cell death of SF767 cancer cells

Author

Terés, Silvia, primary, Lladó, Victoria, additional, Higuera, Mónica, additional, Barceló-Coblijn, Gwendolyn, additional, Martin, M. Laura, additional, Noguera-Salvà, Maria Antònia, additional, Marcilla-Etxenike, Amaia, additional, García-Verdugo, José Manuel, additional, Soriano-Navarro, Mario, additional, Saus, Carlos, additional, Gómez-Pinedo, Ulises, additional, Busquets, Xavier, additional, and Escribá, Pablo V., additional

Published
2012
Full Text
View/download PDF

20. Inhibition of c-Myc Down-Regulation by Sustained Extracellular Signal-Regulated Kinase Activation Prevents the Antimetabolite Methotrexate- and Gemcitabine-Induced Differentiation in Non-Small-Cell Lung Cancer Cells

Author

Serra, Jordi M., primary, Gutiérrez, Antonio, additional, Alemany, Regina, additional, Navarro, María, additional, Ros, Teresa, additional, Saus, Carlos, additional, Ginés, Jordi, additional, Sampol, Antonia, additional, Amat, Juan Carlos, additional, Serra-Moisés, Lorenzo, additional, Martín, Javier, additional, Galmés, Antonio, additional, Vögler, Oliver, additional, and Besalduch, Joan, additional

Published
2008
Full Text
View/download PDF

21. Membrane Structure Modulation, Protein Kinase Cα Activation, and Anticancer Activity of Minerval

Author

Martínez, Jordi, primary, Vögler, Oliver, additional, Casas, Jesús, additional, Barceló, Francisca, additional, Alemany, Regina, additional, Prades, Jesús, additional, Nagy, Tünde, additional, Baamonde, Carmela, additional, Kasprzyk, Philip G., additional, Terés, Silvia, additional, Saus, Carlos, additional, and Escribá, Pablo V., additional

Published
2004
Full Text
View/download PDF

23. Membrane Structure Modulation, Protein Kinase Cα Activation, and Anticancer Activity of Minerval

Author

Martínez, Jordi, Vögler, Oliver, Casas, Jesús, Barceló, Francisca, Alemany, Regina, Prades, Jesús, Nagy, Tünde, Baamonde, Carmela, Kasprzyk, Philip G., Terés, Silvia, Saus, Carlos, and Escribá, Pablo V.

Abstract

Most drugs currently used for human therapy interact with proteins, altering their activity to modulate the pathological cell physiology. In contrast, 2-hydroxy-9-cis-octadecenoic acid (Minerval) was designed to modify the lipid organization of the membrane. Its structure was deduced following the guidelines of the mechanism of action previously proposed by us for certain antitumor drugs. The antiproliferative activity of Minerval supports the above-mentioned hypothesis. This molecule augments the propensity of membrane lipids to organize into nonlamellar (hexagonal HII) phases, promoting the subsequent recruitment of protein kinase C (PKC) to the cell membrane. The binding of the enzyme to membranes was marked and significantly elevated by Minerval in model (liposomes) and cell (A549) membranes and in heart membranes from animals treated with this drug. In addition, Minerval induced increased PKCα expression (mRNA and protein levels) in A549 cells. This drug also induced PKC activation, which led to a p53-independent increase in p21CIP expression, followed by a decrease in the cellular concentrations of cyclins A, B, and D3 and cdk2. These molecular changes impaired the cell cycle progression of A549 cells. At the cellular and physiological level, administration of Minerval inhibited the growth of cancer cells and exerted antitumor effects in animal models of cancer without apparent histological toxicity. The present results support the potential use of Minerval and related compounds in the treatment of tumor pathologies.

Published
2005

24. Fibroqueratoma periungueal adquirido en la edad pediátrica, a propósito de un caso

Author

Corominas, Laura, Fernández-Ansorena, Ana, Saus, Carlos, Corominas, Laura, Fernández-Ansorena, Ana, and Saus, Carlos

Abstract

[Resumen] Objetivo: El fibroqueratoma periungueal adquirido es un tumor fibroepitelial benigno, con escasa incidencia a nivel del pie. Es una tumoración cubierta de piel hiperpigmentada con hiperqueratosis en su porción distal, de consistencia firme e indurada, y tamaño variable, que oscila entre los 3 y los 15 mm. de diámetro. Material y métódos: Presentamos un varón de 6 años de edad, con una tumoración de 0,4 x 0,5 cm, dolorosa compatible con fibroqueratoma periungueal adquirido a nivel del hallux. Dada la edad del paciente, hay que realizar diagnóstico diferencial con tumor de Köenen. Resultados: Tras la resección quirúrgica según técnica de colgajo en bandera, el estudio histopatológico confirma la sospecha clínica. Conclusiones: El fibroqueratoma periungueal adquirido, es una entidad clínica e histológica bien definida y muy característica, cuyo diagnóstico puede realizarse con toda certeza y su tratamiento definitivo se realizará por medio de la escisión definitiva de la lesión., [Abstract] Objective: The acquired periungual fibrokeratoma is a benign fibroepithelial tumor, with little incidence at the level of the foot. It presents as a fleshy mass covered with hyperpigmented skin with hyperkeratosis in its distal portion, firm and indurated consistency, and variable size, ranging from 3 to 15 mm. diameter. Methods: We present a 6-year-old male, who presented at the level of the hallux, a tumor 0.4 x 0.5 cm, painful compatible with fibrokeratoma periungueal acquired. Given the patient's age, a differential diagnosis should be made with Köenen's tumor. Results: After surgical resection according to flag flap technique, the histopathological study confirms the clinical suspicion. Conclusion: Acquired periungueal fibrokeratoma is a well-defined and characteristic clinical and histological entity, whose diagnosis can be made with all certainty and its definitive treatment will be carried out through definitive excision of the lesion.

25. Spontaneous repigmentation of silvery hair in an infant with congenital hydrops fetalis and hypoproteinemia.

Author

Galve J, Martín-Santiago A, Clavero C, Saus C, Alfaro-Arenas R, Pérez-Granero A, Balliu PR, and Ferrando J

Subjects
Agammaglobulinemia complications, Chromosome Aberrations, Congenital Hypothyroidism complications, Hair Diseases complications, Humans, Hydrops Fetalis, Hypopigmentation complications, Hypoproteinemia complications, Infant, Male, Remission, Spontaneous, Hair Diseases pathology, Hypopigmentation pathology
Abstract

Silvery hair is a characteristic finding of 3 rare autosomal recessive disorders: Chédiak-Higashi syndrome (CHS), Elejalde syndrome (ES), and Griscelli syndrome (GS). We report the case of a 2-month-old male infant with transient silvery hair and generalized hypopigmentation of the skin and eyes who did not have one of these classic causative disorders. The patient was delivered at 35 weeks' gestation with congenital hydrops fetalis associated with a chromosomal abnormality (46,XY,add[2],[p23]), hypothyroidism, hypoproteinemia, and hypogammaglobulinemia. Over the course of follow-up, spontaneous brown repigmentation of the silvery hair was noted. We concluded that the silvery hair was induced by hypoproteinemia secondary to congenital hydrops fetalis.

Published
2016

26. Membrane structure modulation, protein kinase C alpha activation, and anticancer activity of minerval.

Author

Martínez J, Vögler O, Casas J, Barceló F, Alemany R, Prades J, Nagy T, Baamonde C, Kasprzyk PG, Terés S, Saus C, and Escribá PV

Subjects
Animals, Cattle, Cell Line, Tumor, Cell Membrane pathology, Dose-Response Relationship, Drug, Enzyme Activation drug effects, Enzyme Activation physiology, Growth Inhibitors pharmacology, Humans, Liposomes, Oleic Acids chemistry, Protein Kinase C-alpha, Antineoplastic Agents pharmacology, Cell Membrane drug effects, Cell Membrane enzymology, Oleic Acids pharmacology, Protein Kinase C metabolism, Stearic Acids pharmacology
Abstract

Most drugs currently used for human therapy interact with proteins, altering their activity to modulate the pathological cell physiology. In contrast, 2-hydroxy-9-cis-octadecenoic acid (Minerval) was designed to modify the lipid organization of the membrane. Its structure was deduced following the guidelines of the mechanism of action previously proposed by us for certain antitumor drugs. The antiproliferative activity of Minerval supports the above-mentioned hypothesis. This molecule augments the propensity of membrane lipids to organize into nonlamellar (hexagonal H(II)) phases, promoting the subsequent recruitment of protein kinase C (PKC) to the cell membrane. The binding of the enzyme to membranes was marked and significantly elevated by Minerval in model (liposomes) and cell (A549) membranes and in heart membranes from animals treated with this drug. In addition, Minerval induced increased PKCalpha expression (mRNA and protein levels) in A549 cells. This drug also induced PKC activation, which led to a p53-independent increase in p21(CIP) expression, followed by a decrease in the cellular concentrations of cyclins A, B, and D3 and cdk2. These molecular changes impaired the cell cycle progression of A549 cells. At the cellular and physiological level, administration of Minerval inhibited the growth of cancer cells and exerted antitumor effects in animal models of cancer without apparent histological toxicity. The present results support the potential use of Minerval and related compounds in the treatment of tumor pathologies.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results